Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
AIRNA logo — The next generation of RNA editing therapeutics

AIRNA

The next generation of RNA editing therapeutics

Founded 2021 United States Cambridge, United States 84 employees Series B Total: $245.00M Biotechnology, Health Care

General Information

Company Name AIRNA
Founded Year 2021
Location United States Cambridge, United States
Founders / Decision Makers
Team member
Employees 84
Industries Biotechnology, Health Care
Funding Stage Series B
Business Model B2B, B2C, B2D
Revenue Model Licensing, Product Sales, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with AIRNA. To contact AIRNA, visit airna.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does AIRNA compare?

A PDF of AIRNA and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting AIRNA soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About AIRNA

AIRNA, founded in 2021, is a biotech company based in the United States that specializes in RNA editing therapeutics. Their mission is encapsulated in the slogan, "The next generation of RNA editing therapeutics." AIRNA aims to revolutionize health care by offering novel solutions for rare and common diseases through their cutting-edge RNA editing platform, RESTORE+.

The company has recently garnered significant attention, highlighted by a substantial $155.00M Series B investment completed on 01 April 2025. This investment round was led by prominent investors including Arch Venture Partners, Venrock, Forbion, Nextech Invest, RTW Investments, and ND Capital. With this financial backing, AIRNA is well-positioned to advance its innovative pipeline and make substantial progress in the biotechnology and health care industries.

Taxonomy: RNA Editing Therapeutics, Biotech Innovation, Rare Diseases Treatment, Common Diseases Treatment, RESTORE+ Platform, Therapeutic Pipeline Development, Health Restoration, Genetic Medicine, RNA Platform Technology, Novel Therapies, Medical Advancements, Precision Medicine

Services & Products

Development of RNA editing therapeutics
Delivering functional cures through genetic medicine
Optimizing and personalizing treatment solutions

Target Customers

Patients with rare diseases Patients with common conditions Healthcare providers Research institutions

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $155.00M 6
Arch Venture Partners Venrock Forbion
Arch Venture Partners, Venrock +4
01 Apr 2025
Series A $60.00M 5
Arch Venture Partners Forbion Alexandria Venture Investments
Arch Venture Partners, Forbion +3
01 Jul 2024
Early VC $30.00M 5
Arch Venture Partners Fast Track Initiative Codon Capital
Arch Venture Partners, Fast Track Initiative +3
01 Sep 2023

AIRNA Alternatives & Competitors

View All Alternatives
AIRNA vs
Alltrna
Alltrna United States

The world’s first transfer RNA (tRNA) platform company. We are unlocking the vast therapeutic potent...

Series B
49 employees
Biotechnology, Health Care
AIRNA vs
Avidity Biosciences, Inc.
Avidity Biosciences, Inc. United States

At Avidity, we are developing a new class of oligonucleotide-based therapies.

IPO
447 employees
Biotechnology, Health Care
AIRNA vs
miRecule, Inc.
miRecule, Inc. United States

RNA Therapeutics

Seed
12 employees
Biopharma, Biotechnology
View all alternatives

FAQ About AIRNA

The next generation of RNA editing therapeutics
AIRNA was founded in 2021.
AIRNA is headquartered in Cambridge, United States.
AIRNA operates in Biotechnology and Health Care. Its work centres on RNA Editing Therapeutics, Biotech Innovation, Rare Diseases Treatment and Common Diseases Treatment. Its customers include Patients with rare diseases, Patients with common conditions and Healthcare providers.
AIRNA has a B2B, B2C and B2D business model. Its revenue comes from Licensing, Product Sales and Service Fee.
AIRNA has approximately 84 employees.
AIRNA has completed 3 funding rounds, raising a total of $245.00M. The latest funding stage is Series B.
AIRNA offers: Development of RNA editing therapeutics, Delivering functional cures through genetic medicine, Optimizing and personalizing treatment solutions.
Top alternatives and competitors to AIRNA include Alltrna, Avidity Biosciences, Inc., miRecule, Inc., ADARx Pharmaceuticals Inc., BIORCHESTRA Co., Ltd.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AIRNA and Alltrna are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for AIRNA, https://bouncewatch.com/company/airna, updated 30 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes